Answers are grounded in this paper and cite their sources.
Webinar reveals insights on neurodegeneration biomarkers and the role of molecular imaging in diagnostics and treatments.
Neurodegeneration is a complex multifactorial process that causes neuronal death in brain and spinal cord, resulting in a series of dementia and movement disorders. Neurodegeneration is accompanied by abnormal protein aggregation, oxidative stress, neuroinflammation, axonal transport deficits, calcium deregulation, mitochondrial dysfunction, and abnormal neuron-glial interactions. The demand for in vivo technologies to identify neurodegenerative biomarkers is at the leading edge for pathogenic study, diagnostic development, and therapeutic intervention of these devastating disorders. This webinar provides a comprehensive review of the role of molecular imaging in neurodegeneration and current applications of neuroimaging in neurodegenerative disorders as well as quantification and semi-quantification methods for neuroimaging. Imaging methods such as nuclear medicine (PET, SPECT) in clinical practice and preclinical optical imaging approaches are also covered, as well as an update on novel molecular probes.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: